ATE261954T1 - Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen - Google Patents

Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen

Info

Publication number
ATE261954T1
ATE261954T1 AT99963141T AT99963141T ATE261954T1 AT E261954 T1 ATE261954 T1 AT E261954T1 AT 99963141 T AT99963141 T AT 99963141T AT 99963141 T AT99963141 T AT 99963141T AT E261954 T1 ATE261954 T1 AT E261954T1
Authority
AT
Austria
Prior art keywords
inhibitors
derivatives
matrix metalloproteinases
tricyclic sulfonamides
sulfonamides
Prior art date
Application number
AT99963141T
Other languages
English (en)
Inventor
Patrick Michael O'brien
Joseph Armand Picard
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE261954T1 publication Critical patent/ATE261954T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H04M15/30—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal the meter or calculation of charges not being controlled from an exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/31—Distributed metering or calculation of charges
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/49—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/80—Rating or billing plans; Tariff determination aspects
    • H04M15/8044—Least cost routing
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/83—Notification aspects
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/01—Details of billing arrangements
    • H04M2215/0168—On line or real-time flexible customization or negotiation according to wishes of subscriber
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/42—Least cost routing, i.e. provision for selecting the lowest cost tariff
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/46—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/74—Rating aspects, e.g. rating parameters or tariff determination apects
    • H04M2215/745—Least cost routing, e.g. Automatic or manual, call by call or by preselection
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/82—Advice-of-Charge [AOC], i.e. notify subscriber of charges/cumulative charge; meter at the substation
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/92—Autonomous calculations of charges in terminal, i.e. meter not controlled from exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/96—Distributed calculation of charges, e.g. in different nodes like for mobiles between HLR and VLR, or between the terminal and the billing function

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
AT99963141T 1998-07-30 1999-06-02 Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen ATE261954T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9500698P 1998-07-30 1998-07-30
PCT/US1999/012273 WO2000006561A1 (en) 1998-07-30 1999-06-02 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
ATE261954T1 true ATE261954T1 (de) 2004-04-15

Family

ID=22248526

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99963141T ATE261954T1 (de) 1998-07-30 1999-06-02 Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen

Country Status (32)

Country Link
US (2) US6420408B1 (de)
EP (1) EP1100792B1 (de)
JP (1) JP2002521478A (de)
KR (1) KR20010072089A (de)
CN (1) CN1310716A (de)
AP (1) AP2001002037A0 (de)
AT (1) ATE261954T1 (de)
AU (1) AU758619B2 (de)
BG (1) BG105185A (de)
BR (1) BR9912600A (de)
CA (1) CA2335077A1 (de)
DE (1) DE69915634T2 (de)
DK (1) DK1100792T3 (de)
EA (1) EA200100158A1 (de)
EE (1) EE200100063A (de)
ES (1) ES2216614T3 (de)
GE (1) GEP20033052B (de)
HR (1) HRP20010078A2 (de)
HU (1) HUP0102714A3 (de)
ID (1) ID27192A (de)
IL (1) IL140746A0 (de)
IS (1) IS5810A (de)
NO (1) NO20010479D0 (de)
NZ (1) NZ509439A (de)
OA (1) OA11589A (de)
PL (1) PL345776A1 (de)
PT (1) PT1100792E (de)
SK (1) SK1192001A3 (de)
TR (1) TR200100239T2 (de)
WO (1) WO2000006561A1 (de)
YU (1) YU6701A (de)
ZA (1) ZA200100455B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
AR034390A1 (es) * 2001-08-03 2004-02-25 Schering Corp Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa
WO2003032974A2 (en) * 2001-10-12 2003-04-24 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2471099C (en) * 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
KR20050010882A (ko) * 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
AU2003281169A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
ATE517926T1 (de) 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
US20060112494A1 (en) * 2004-12-01 2006-06-01 David Oppong Method of protecting an animal skin product from metalloproteinase activity
CN101702906B (zh) 2007-02-23 2014-02-12 耶达研究及发展有限公司 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物
US8012947B2 (en) * 2007-03-15 2011-09-06 Hospital For Special Surgery Methods and compositions for promoting wound healing
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
CA2676946A1 (en) 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
AU2011306398A1 (en) 2010-09-24 2013-05-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US11780934B2 (en) 2016-02-05 2023-10-10 Institut Pasteur Use of inhibitors of ADAM12 as adjuvants in tumor therapies
CN114981251B (zh) * 2020-01-21 2023-11-21 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH517068A (de) * 1969-07-09 1971-12-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäurederivaten
CH531501A (de) * 1970-03-20 1972-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioalkansäuren, ihren Salzen und funktionellen Derivaten
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
EP0828726B1 (de) 1995-06-02 2001-10-04 Warner-Lambert Company Trizyklische verbindungen als matrix-metalloproteinase inhibitoren
US5883940A (en) 1996-07-01 1999-03-16 Teledynamics Group, Inc. Interactive method and apparatus for the generation of leads
ES2231879T3 (es) 1996-08-16 2005-05-16 Warner-Lambert Company Llc Inhibidores de metaloproteinasas de la matriz de acido butirico.
AU735013B2 (en) * 1996-09-04 2001-06-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
JP2002514180A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
HUP0000641A3 (en) * 1996-10-16 2001-02-28 American Cyanamid Company Madi Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NZ509439A (en) 2002-10-25
YU6701A (sh) 2003-12-31
DK1100792T3 (da) 2004-07-05
WO2000006561A1 (en) 2000-02-10
DE69915634T2 (de) 2004-08-12
IS5810A (is) 2001-01-12
ZA200100455B (en) 2002-01-16
ES2216614T3 (es) 2004-10-16
ID27192A (id) 2001-03-08
JP2002521478A (ja) 2002-07-16
US6492422B2 (en) 2002-12-10
SK1192001A3 (en) 2002-02-05
CA2335077A1 (en) 2000-02-10
KR20010072089A (ko) 2001-07-31
NO20010479L (no) 2001-01-29
BG105185A (en) 2002-04-30
HUP0102714A3 (en) 2003-01-28
US20020169164A1 (en) 2002-11-14
GEP20033052B (en) 2003-08-25
AU758619B2 (en) 2003-03-27
IL140746A0 (en) 2002-02-10
TR200100239T2 (tr) 2001-05-21
CN1310716A (zh) 2001-08-29
HRP20010078A2 (en) 2002-02-28
PT1100792E (pt) 2004-08-31
EP1100792B1 (de) 2004-03-17
AP2001002037A0 (en) 2001-03-31
NO20010479D0 (no) 2001-01-29
US6420408B1 (en) 2002-07-16
BR9912600A (pt) 2001-05-02
EA200100158A1 (ru) 2001-08-27
PL345776A1 (en) 2002-01-02
HUP0102714A2 (hu) 2002-01-28
EP1100792A1 (de) 2001-05-23
EE200100063A (et) 2002-06-17
AU4329299A (en) 2000-02-21
OA11589A (en) 2004-07-30
DE69915634D1 (de) 2004-04-22

Similar Documents

Publication Publication Date Title
ATE261954T1 (de) Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen
ATE295361T1 (de) Dimerverbindungen und als inhibitoren der neuramidinase
ATE382042T1 (de) Sulfonamidderivate als wirkstoff-vorläufer von inhibitoren der aspartyl-protease
ATE205714T1 (de) Sulfonamide und ihre verwendung
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
ATE330950T1 (de) Heterocyclische sulfonamide als inhibitoren der beta-amyloid-produktion
DE60227686D1 (de) Mischungen von cyclosporin-analogen und ihre verwendung als immunmodulatoren
ATE344246T1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
NO20014135L (no) Nye sulfonamidforbindelser og deres anvendelse
DE69739003D1 (de) Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren
DE60122196D1 (de) Synergistische antioxidans-kombination von delta tocols und polyphenolen
PT1086076E (pt) Inibidores de sulfonamida de aspartil protease
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
ATE178598T1 (de) Sulfonamid inhibitoren von hiv-aspartyl protease
ATE348816T1 (de) 2,5-dioxoimidazolidin-4-ylacetamide und analoga als inhibitoren von metalloproteinase mmp12
DE60123461D1 (de) Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel
DE60234167D1 (de) Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
DE59912795D1 (de) Substituierte Benzamide und ihre Verwendung als Immunmodulatoren
ATE277902T1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
TR200002877T2 (tr) Sülfonamid türevleri
DE69801878D1 (de) Verwendung von Oxamatderivaten als Depigmentierungsmittel
PT1446399E (pt) Derivados de piperazina tendo actividade antagonista de sst1
ATE260273T1 (de) Neue thiochromanderivate und ihre verwendung als thrombininhibitoren
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
ATE169618T1 (de) Piperidinylamide, sulfonamide und sulfoxamide als inhibitoren der cholesterin biosynthese

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1100792

Country of ref document: EP

REN Ceased due to non-payment of the annual fee